The frequency of AXL somatic mutations in those cancer types is low (5.5%; 34 mutations in 616 patients, Supplementary Dataset S1Z) compared to TP53 (Supplementary Figure S9, Supplementary Dataset S1AA). This evidence concerns the gene TP53 and cancer.